According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.
Recent News
Profactor Pharma Announces Issuance of Indian and Eurasian Patent Covering a high yielding cell line for treatment of Haemophilia A
ProFactor Pharma Ltd (PFP) the developer of a unique, ultra high yielding cell line for the manufacture of recombinant human factor VIII (rhVIII), is pleased to announce the recent issuance of Indian Patent No. 361851 and...
Profactor Pharma completes optimisation of process for manufacture of lowest cost recombinant FVIII
Scottish biotech business ProFactor Pharma Ltd: (PFP) has completed the optimisation of its process for the manufacture of recombinant Factor VIII, for the treatment of Haemophilia A. In July 2020 we reported on the important development milestone that had been...